Biopharmaceuticals are pharmaceutical products consisting of (glyco)proteins. Nowadays a substantial part of the FDA-approved drugs belong to this class of drugs.
Shifting paradigms: biopharmaceuticals versus low molecular weight drugs
Biosimilars/Research
|
Posted 30/07/2009
0
Post your comment
According to Professor Daan Crommelin et al. of the Utrecht Institute for Pharmaceutical Sciences at Utrecht and OctoPlus at Leiden, The Netherlands, biopharmaceuticals deserve special attention as they have a number of characteristics that set them aside from low molecular weight drugs.
Their activity depends on their complicated shape based on secondary, tertiary and (sometimes) quaternary structures. These structures cannot be fully defined with our present set of analytical techniques and approaches for potency testing. They are often the same as (or closely resemble) endogenous proteins. This means that in safety testing and clinical test programmes questions have to be addressed regarding species specific responses, selection of dosing schedules and route of administration, and the possible occurrence of immunogenicity. As the conformational structure of a protein is easily disturbed, formulation and handling of biopharmaceuticals needs special attention in order to optimise the therapeutic effect and minimise adverse reaction, amongst which immune responses.
The issue of biogenerics is gaining more and more interest and different critical elements in the development of biogenerics are touched upon.
They conclude that biopharmaceuticals cannot be characterised fully in terms of their structure like low molecular weight drugs. The performance of biopharmaceuticals relies on strict production protocols and close monitoring of their activity in the clinical situation.
Source: Int J Pharm. 2003;266:3-16.
News
FDA approves first eculizumab biosimilar Bkemv for two rare diseases
EC biosimilar approvals: Omlyclo, Jubbonti/Wyost, and Pyzchiva
General
Boehringer Ingelheim to expand access to adalimumab biosimilar
Challenges and progress in the registration of biosimilars in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma
Tocilizumab and pembrolizumab biosimilar advances for Korean firms
Unveiling key clinical findings for denosumab biosimilar candidates
Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma
![147 AA010665 147 AA010665](/var/gabi/storage/images/media/images/147-aa010665/46111-1-eng-GB/147-AA010665_large.jpg)
Biosimilars/Research Posted 09/07/2024
Tocilizumab and pembrolizumab biosimilar advances for Korean firms
![36 AA010641 36 AA010641](/var/gabi/storage/images/media/images/36-aa010641/44274-1-eng-GB/36-AA010641_large.jpg)
Biosimilars/Research Posted 03/07/2024
Unveiling key clinical findings for denosumab biosimilar candidates
![03 AA010722 03 AA010722](/var/gabi/storage/images/media/images/03-aa010722/46138-1-eng-GB/03-AA010722_large.jpg)
Biosimilars/Research Posted 07/05/2024
Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
![Pharmacokinetics 1 V13K15 Pharmacokinetics 1 V13K15](/var/gabi/storage/images/media/images/pharmacokinetics-1-v13k15/20251-1-eng-GB/Pharmacokinetics-1-V13K15_large.jpg)
Biosimilars/Research Posted 16/04/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment